Note: Descriptions are shown in the official language in which they were submitted.
CA 02511143 2008-02-05
WO 2004/056754 PCT/DK2003/000907
PREPARATION OF RACEMIC AND/OR S- OR R-CITALOPRAM
DIOLS AND THEIR USE FOR THE PREPARATION RACEMIC
AND/OR S- OR R-CITALOPRAM
The invention relates to a process for the preparation of racemic citalopram
diol and
R- or S-citaloprain diol by separating an initial non-racemic mixture of the
compounds
R- and S-citalopram diol (R- and S-4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-
hydroxybutyl]-3-(hydroxymethyl)-benzonitrile) into a fraction of racemic
citalopram
diol and a fraction being enriched with S-diol or R-diol. The invention also
relates to
the use of such isolated citalopram diols for the formation of the
corresponding
racemic citalopram and/or S- or R-citalopram to be comprised in a
pharmaceutical
composition.
Background of the invention
Citalopram is a well-known antidepressant drug that has now been on the market
for
some years and has the following structure:
N
O H3
N
W, CH3
Citalopram may be prepared by ring closure of 4-[4-(dimethylamino)-1-(4'-
fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)-benzonitrile (racemic
citalopram
diol) as described in US patent No. 4,650,884. The product citalopram is a
racemic
mixture of the R- and S-enantiomers.
Further, the S-enantiomer of citalopram (escitalopram) is a valuable
antidepressant of
the selective serotonin reuptake inhibitor (SSRI) type. Escitalopram may be
prepared
CA 02511143 2005-06-20
WO 2004/056754 PCT/DK2003/000907
2
by ring closure of S-4-[4-(dimethylamino)-1-(4'-fluorophenyl)-l-hydroxybutyl]-
3-
(hydroxymethyl)-benzonitrile (S-diol) with retention of configuration as
described in
EP B1 347 066. The amount of R-citalopram compared to S-citalopram in the
product
escitalopram should be less than 3%.
Furthermore, a method for the preparation of a mixture of R- and S-citalopram
with
more than 50% of the S-enatiomer from a mixture of R- and S-diol with more
than
50% of the R-diol is described in W003000672.
It appears from the above, that products of racemic citalopram and
escitalopram with
the above-mentioned enantiomeric purity are required for the preparation of
pharmaceutical compositions and that racemic citalopram and escitalopram
products
may be prepared by ring closure of the RS-diol and R-diol and/or S-diol. As a
consequence, methods for the preparation of products of racemic diol and S-
diol being
correspondingly enantiomerically pure are required.
Processes for the preparation and purification of R- or S-diol products are
available.
Such processes involve for instance enantio-selective synthesis as described
in EP
0347066, classical resolution and chromatographic separation as described in
W003006449. Depending on the specific process and the conditions used, the
enantiomeric purity of the S-diol product may have to be improved before the S-
diol
product will meet the above requirements.
Surprisingly, it has now been found that by using the process of the invention
an
expensive, but apparently useless S-diol product being contaminated with R-
diol, may
easily be converted into the two valuable products, racemic diol and S-diol,
which
meet the above requirements as regards enantiomeric purity.
Furthermore, by using the process of the invention, an expensive, but
apparently
useless R-diol product being contaminated with S-diol, may easily be converted
into
the valuable products, racemic diol and R-diol, which meet the above
requirements as
regards enantiomeric purity.
CA 02511143 2005-06-20
WO 2004/056754 PCT/DK2003/000907
3
More particularly, the present invention provides a process for the separation
of an
initial non-racemic mixture of R- and S-4-[4-(dimethylamino)-1-(4'-
fluorophenyl)-1-
hydroxybutyl]-3-(hydroxymethyl)-benzonitrile with more than 50% of one of the
enantiomers into a fraction being enriched with S-diol or R-diol and a
fraction
comprising RS-diol, wherein the ratio of R-diol:S-diol is equal to 1:1 or
closer to 1:1
than in the initial mixture of R- and S-diol.
The process of the invention is important and very useful, in particular
because it
provides a convenient, cheap and efficient way to transform a mixture of R-
and S-
diols which does not meet the above requirements as regards enantiomeric
purity into
two valuable products, RS-diol and S-diol (or R-diol), which meet the above
requirements as regards enantiomeric purity.
In another aspect, the invention provides a convenient, cheap and efficient
method for
making an intermediate to be used in the manufacturing of citalopram and
escitalopram.
With the present invention, the process for the production of racemic
citalopram and
escitalopram meeting the requirements of the respective marketing approvals
has
become more rational and more economical as regards the simplicity of the
process
and the utilisation of reagents and resources.
Summary of the Invention
Thus, the present invention relates to a process for the preparation of
racemic diol free
base and/or acid addition salt and/or R- or S-diol free base and/or an acid
addition salt
comprising a separation of an initial non-racemic mixture of R- and S-diol
free base
and/or acid addition salt with more than 50% of one of the enantiomers into a
fraction
being enriched with S-diol or R-diol free base and/or acid addition salt and a
fraction
comprising RS-diol free base and/or acid addition salt wherein the ratio of R-
diol:S-
diol is equal to 1:1 or closer to 1:1 than in the initial mixture of R- and S-
diol wherein
CA 02511143 2008-02-05
WO 2004/056754 PCT/DK2003/000907
4
i) RS-diol free base and/or acid addition salt is precipitated from a
solution of the initial non-racemic mixture of R- and S-diol free base
and/or acid addition salt; or
R- or S-diol free base and/or acid addition salt is dissolved into a
solvent from the initial non-racemic mixture of R- and S-diol free base
and/or acid addition salt in said solvent, leaving a residue comprising
RS-diol free base and/or acid addition salt;
ii) the residue/precipitate formed is separated from the final solution
phase;
iia) if the residue/precipitate is crystalline it is optionally
recrystallised one or more times to form racemic diol;
iib) if the residue/precipitate is not crystalline, steps i) and ii) are
optionally repeated until a crystalline residue/precipitate is
obtained and the crystalline residue/precipitate is optionally
recrystallised one or more times to form racemic diol;
iii) the final solution phase is optionally subjected to further purification
and S-diol or R-diol free base and/or acid addition salt is isolated from
the final solution phase;
iv) the free bases of the diols obtained are optionally converted to acid
addition salts thereof or acid addition salts of the diols obtained are
optionally converted to other acid addition salts or acid addition salts
of the diols obtained are optionally converted to the corresponding free
bases.
CA 02511143 2008-02-05
4a
The invention also provides a process for the preparation of racemic
citalopram diol free
base and/or acid addition salt and/or R- or S-citalopram diol free base and/or
acid addition salt
comprising a separation of an initial non-racemic mixture of R- and S-
citalopram diol free base
and/or acid addition salt with more than 50% of one of the enantiomers into a
fraction being
enriched with S-citalopram diol or R-citalopram diol free base and/or acid
addition salt and a
fraction comprising RS-citalopram diol free base and/or acid addition salt
wherein the ratio of R-
citalopram diol:S-citalopram diol is equal to 1:1 or closer to 1:1 than in the
initial mixture of R-
and S-citalopram diol characterized in that
i) RS-citalopram diol free base and/or acid addition salt is precipitated from
a
solution of the initial non-racemic mixture of R- and S-citalopram diol free
base and/or
acid addition salt; or
R- or S-citalopram diol free base and/or acid addition salt is dissolved into
a solvent from
the initial non-racemic mixture of R- and S-citalopram diol free base and/or
acid addition
salt in said solvent, leaving a residue comprising RS-citalopram diol free
base and/or acid
addition salt;
ii) the residue/precipitate formed is separated from the final solution phase;
iia) if the residue/precipitate is crystalline it is optionally recrystallised
one or
more times to form racemic citalopram diol;
iib) if the residue/precipitate is not crystalline, steps i) and ii) are
optionally
repeated until a crystalline residue/precipitate is obtained and the
crystalline
residue/precipitate is optionally recrystallised one or more times to form
racemic citalopram diol;
iii) the final solution phase is optionally subjected to further purification
and S-
citalopram diol or R-citalopram diol free base and/or acid addition salt is
isolated from the
final solution phase ;
CA 02511143 2008-02-05
4b
iv) the free bases of the citalopram diols obtained are optionally converted
to acid
addition salts thereof or acid addition salts of the citalopram diols obtained
are optionally
converted to other acid addition salts or acid addition salts of the
citalopram diols obtained
are optionally converted to the corresponding free bases.
Accordingly, the RS-diol free base and/or acid addition salt obtained gives
rise to the
final solution phase being enriched with either the S- or R-diol free base
and/or acid
addition salt. The surplus of R- or S-diol free base and/or acid addition salt
may then
be isolated from the final solution phase as described below.
CA 02511143 2005-06-20
WO 2004/056754 PCT/DK2003/000907
According to a specific embodiment, the invention relates to a process for the
preparation of racemic diol free base and/or acid addition salt using the
process
described above.
5 According to another specific embodiment, the invention relates to a process
for the
preparation of S-diol (or R-diol) free base and/or an acid addition salt using
the
process described above.
According to still another specific embodiment, the invention relates to the
use of the
prepared racemic diol free base and/or acid addition salt and/or S-diol (or R-
diol) free
base and/or an acid addition salt for the preparation of racemic citalopram
and/or S-
citalopram (or R-citalopram) free base and/or acid addition salt using the
process
described below.
Detailed description of the invention
Whenever used in this document, the terms "S-diol" and "S-citalopram diol"
mean S-
4- [4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl] -3 -(hydroxymethyl)
benzonitrile.
Whenever used in this document, the terms "R-diol" and "R-citalopram diol"
mean R-
4-[4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)
benzonitrile.
Whenever used in this document, the term "RS-diol" means a mixture of R- and S-
diol
such as a 0.5:1.5 or 0.9:1.1 or 0.95:1.05 or 0.98:1.02 or 0.99:1.01 mixture of
R- and S-
diol and preferably a mixture with a 1:1 ratio of the R- and S-diol.
Whenever used in this document, the terms "diol enantiomer" and "diol isomer"
mean
either S- or R-diol.
CA 02511143 2005-06-20
WO 2004/056754 PCT/DK2003/000907
6
Whenever used in this document, the term "racemic diol" means a 1:1 mixture of
the
R- and S-diols. The term "non-racemic mixtures of diols" means mixtures which
contain R- and S-diols in a ratio other than 1:1.
Whenever used in this document, the terms "citalopram enantiomer" and
"citalopram
isomer" mean either S- or R-citalopram.
Whenever used in this document, the term "racemic citalopram" means a 1:1
mixture
of R- and S-citalopram. The term "non-racemic citalopram" means mixtures which
contain R- and S-citalopram in a ratio other than 1:1.
As used in this description, the term "precipitation" means forming a
precipitate, in
the form of crystals, an amorphous solid or an oil or mixtures thereof, from a
solution
of the initial non-racemic mixture of R- and S-diol in a solvent. In the
present
description, a precipitate maybe an oil, an amorphous solid or crystals or
mixtures
thereof.
As used in this description, the term "residue" refers to the residue
remaining after
dissolving R- or S-diol into a solvent from an initial non-racemic mixture of
R- or S-
diols. The residue maybe in the form of crystals, an amorphous solid or an oil
or
mixtures thereof.
As used herein, the term "residue/precipitate" refers to either a precipitate
or a residue
as defined above.
As used herein, the term "mother liquor" means the solvent remaining after
removal
or separation from the precipitate.
As used herein, the term "organic and/or aqueous phase resulting from the
selective
dissolution of R- or S-diol" refers to the phase wherein R- or S-diol is
dissolved from
an initial non-racemic mixture of R- or S-diols.
CA 02511143 2005-06-20
WO 2004/056754 PCT/DK2003/000907
7
As used herein, the term "final solution phase" refers to a mother liquor or
an organic
and/or aqueous phase resulting from the selective dissolution of R- or S-diol
as
defined above.
As already mentioned, the above processes for the preparation of citalopram
free base
and/or acid addition salt and/or escitalopram free base and/or acid addition
salt may
result in a mixture of R- and S-citalopram free base and/or acid addition salt
which is
not acceptable for pharmaceutical use. According to the present invention, a
surprisingly efficient process for the preparation of racemic diol and R- or S-
diol free
base and/or acid addition salt to be used for the preparation of raceinic
citalopram free
base and/or acid addition salt and R- or S-citalopram free base and/or acid
addition
salt has been found.
This new process involves the separation of an initial non-racemic mixture of
R- and
S-diol free base and/or acid addition salt into a fraction of racemic diol
free base
and/or acid addition salt and a fraction of R- or S-diol free base and/or acid
addition
salt. The fraction of racemic diol free base and/or acid addition salt is
precipitated as
an oil, an amorphous solid or in crystalline form or mixtures thereof from a
solvent,
and the R- or S-diol free base and/or acid addition salt is isolated from the
final
solution phase. Then, racemic citalopram free base and/or acid addition salt
and R- or
S-citalopram free base and/or acid addition salt may be formed from the
corresponding racemic diol free base and/or acid addition salt and R- or S-
diol free
base and/or acid addition salt by ring closure.
According to another aspect of the invention, the initial non-racemic mixture
of R-
and S-diol free base and/or acid addition salt is separated into a fraction
being
enriched with S-diol or R-diol free base and/or acid addition salt and a
fraction
comprising RS-diol free base and/or acid addition salt wherein the ratio of R-
diol:S-
diol is equal to 1:1 or closer to 1:1 than in the initial mixture of R- and S-
diol by
mixing the initial non-raceinic mixture of R- and S-diol free base and/or acid
addition
salt with a solvent and allowing preferentially the R- or S-diol free base
and/or acid
addition salt to dissolve in the solvent followed by separation of the
undissolved RS-
diol free base and/or acid addition salt residue from the organic and/or
aqueous phase
CA 02511143 2005-06-20
WO 2004/056754 PCT/DK2003/000907
8
resulting from the selective dissolution of R- or S-diol free base and/or acid
addition
salt and isolation of R- and S-diol free base and/or acid addition salt from
said
solvent.
The solvent used according to this embodiment of the invention is any solvent
which
allow preferentially the R-or S-diol free base and/or acid addition salt to
dissolve
leaving a mixture of RS-diol free base and/or an acid addition salt wherein
the ratio of
R-diol:S-diol is equal to 1:1 or closer to 1:1 than in the initial mixture of
R- and S-diol
as a residue. Useful solvents are solvents such as those mentioned for the
precipitation
of RS-diol free base and/or RS-diol acid addition salts.
The initial non-racemic mixture of R- and S- diol free base and/or acid
addition salt
used in the process of the invention may be an oil, an amorphous solid or in
crystalline form; or mixtures thereof.
The residue/precipitate formed in step i) may be an oil, an amorphous solid or
in
crystalline form; or a mixture thereof. The residue/precipitate formed in step
i) is
preferably in crystalline form.
According to one embodiment of the invention, the initial non-racemic mixture
of R-
and S- diol free base and/or acid addition salt used in the process of the
invention
contains more than 50% of S-diol, or more preferred more than 70% of S-diol or
most
preferred more than 90% of S-diol.
According to another embodiment of the invention, the initial non-racemic
mixture of
R- and S-diol free base and/or acid addition salt used in the process of the
invention
contains less than 99.9% of S-diol, such as less than 99.5% of S-diol, or less
than 99%
S-diol, or less than 98% of S-diol.
Accordingly, the initial non-racemic mixture of R- and S-diol free base and/or
acid
addition salt may contain 50%-98% of S-diol, or 50%-99% of S-diol, or 50%-
99.5%
of S-diol, or 50%-99.9% of S-diol, or 70%-98% of S-diol, or 70%-99% of S-diol,
or
CA 02511143 2005-06-20
WO 2004/056754 PCT/DK2003/000907
9
70%-99.5% of S-diol, or 70%-99.9% of S-diol, or 90%-98% of S-diol, or 90%-99%
of
S-diol, or 90%-99.5% of S-diol, or 90%-99.9% of S-diol.
According to another embodiment of the invention, the initial non-racemic
mixture of
R- and S-diol free base and/or acid addition salt used in the process of the
invention
contains more than 50% of R-diol, or more preferred more than 70% of R-diol or
most
preferred more than 90% of R-diol.
According to yet another embodiment of the invention, the initial non-racemic
mixture of R- and S-diol free base and/or acid addition salt used in the
process of the
invention contains less than 99.9% of R-diol, such as less than 99.5% of R-
diol, or less
than 99% R-diol, or less than 98% of R-diol.
Accordingly, the initial non-racemic mixture of R- and S-diol free base and/or
acid
addition salt may contain 50%-98% of R-diol, or 50%-99% of R-diol, or 50%-
99.5%
of R-diol, or 50%-99.9% of R-diol, or 70%-98% of R-diol, or 70%-99% of R-diol,
or
70%-99.5% of R-diol, or 70%-99.9% of R-diol, or 90%-98% of R-diol, or 90%-99%
of R-diol, or 90%-99.5% of R-diol, or 90%-99.9% of R-diol.
The process may be repeated until a racemic mixture of R- and S-diols is
obtained
and/or until the desired degree of enantiomeric purity of the R- or S-diol is
obtained.
According to one embodiment of the invention, the RS-diol of the
residue/precipitate
is in the form of a free base and/or an acid addition salt; and independently
thereof the
R- or S-diol of the final solution phase is in the form of a free base and/or
an acid
addition salt. Accordingly, when the RS-diol comprised in the
residue/precipitate is in
the form of a free base, then the R- or S-diol comprised in the final solution
phase,
may be in the form of a free base, an acid addition salt or a mixture of a
free base and
an acid addition salt. Furthermore, when the RS-diol comprised in the
residue/precipitate is in the form of an acid addition salt, then the R- or S-
diol
comprised in the final solution phase, may be in the form of a free base, an
acid
addition salt or a mixture of a free base and acid addition salt. Finally,
when the RS-
diol comprised in the residue/precipitate is a mixture of a free base and an
acid
CA 02511143 2005-06-20
WO 2004/056754 PCT/DK2003/000907
addition salt, then the R- or S-diol comprised in the final solution phase,
may be in the
form of a free base, an acid addition salt or a mixture of a free base and
acid addition
salt.
5 The initial non-racemic mixture of R- and S- diol used in the process of the
invention
may be present as the free base, as salts, or as a mixture of free bases and
salts.
Furthermore, the free bases of the diols obtained are optionally converted to
acid
addition salts thereof or acid addition salts of the diols obtained are
optionally
10 converted to other acid addition salts or acid addition salts of the diols
obtained are
optionally converted to the corresponding free bases by methods known to those
skilled in the art.
Precipitation of the RS-diol free base may be carried out by obtaining or
dissolving
the non-racemic mixture of R- and S-diol free base and/or acid addition salt
in a
suitable solvent, optionally by applying heat, and then allowing the solution
to cool,
or by cooling to below ambient temperature. The precipitate is then separated
from
the mother liquor, preferably by filtration or decanting.
A residue of RS-diol free base may be formed by selective dissolution of R- or
S-diol
free base and/or acid addition salt into a solvent from the initial non-
racemic mixture
of R- and S-diols free base and/or acid addition salt in said solvent. The
residue is then
separated from the organic and/or aqueous phase resulting from the selective
dissolution of R- or S-diol.
If the residue/precipitate is crystalline, the crystals are optionally
recrystallised one or
more times to form racemic diol free base. Then, racemic citalopram free base
may be
formed from the racemic diol free base by ring closure. The free base of
racemic
citalopram may optionally be converted to an acid addition salt thereof,
preferably the
hydrobromide salt.
CA 02511143 2005-06-20
WO 2004/056754 PCT/DK2003/000907
11
If the residue/precipitate formed is an oil or an amorphous solid, steps i)
and ii) may
be repeated until a crystalline product is obtained. The crystals obtained are
optionally recrystallised one or more times to form racemic diol free base.
Racemic
citalopram free base may be formed from the racemic diol free base by ring
closure.
The free base of racemic citalopram is optionally converted to an acid
addition salt
thereof, preferably the hydrobromide salt.
The RS-diol free base prepared according to the invention is optionally
converted to
acid addition salts thereof.
An oily phase separated from the final solution phase is optionally subjected
to
conventional purification processes.
The RS-diol free base prepared according to the invention may contain a minor
excess
of the S-diol (or R-diol). It may thus be necessary to repeat steps i) and ii)
(in
particular crystallisation) of the RS-diol free base one or more times in
order to obtain
racemic diol. The final solution phases may be pooled together and the diol
enantiomer contained herein may be isolated as described below.
Suitable solvents for obtaining the residue/precipitate comprising the RS-diol
free
base are apolar solvents for example alkanes, such as heptane or hexane,
aromatic
hydrocarbons such as toluene, benzene and xylene, polar solvents such as
acetonitrile,
alcohols such as methanol and iso-propylalcohol or ketones such as methyl
isobutyl
ketone; or mixtures thereof.
In a preferred embodiment, a free base of the RS-diol is obtained in step i),
preferably
in crystalline form.
If necessary, crystallisation may be initiated by seeding with racemic
crystalline diol
free base.
CA 02511143 2005-06-20
WO 2004/056754 PCT/DK2003/000907
12
The precipitation of RS-diol acid addition salt may be carried out by
obtaining or
dissolving the non-racemic mixture of R- and S-diol free base or acid addition
salt in a
suitable solvent, if necessary by applying heat, and adding an acid, for
example as a
solid, a liquid, in a solution or as a gas.
The acid used for the precipitation of a RS-diol acid addition salt is an acid
which
precipitates a mixture of R- and S-enantiomers and leaves the mother liquor
enriched
with either the R- or S-diol enantiomer of the diol as the free base or an
acid addition
salt.
The acid used for the precipitation of a RS-diol acid addition salt may be:
= added after the initial non-racemic mixture of R- and S-diol free base
and/or acid addition salt is obtained or dissolved in a suitable solvent;
and/or
= present in the solvent during and/or prior to dissolution of the initial non-
racemic mixture of R- and S-diol free base and/or acid addition salt; and/or
= present in the initial non-racemic mixture of R- and S-diol free base and/or
acid addition salt during and/or prior to dissolution in the solvent.
A residue of RS-diol acid addition salt may be formed by selective dissolution
of R- or
S-diol free base and/or acid addition salt into a solvent from the initial non-
racemic
mixture of R- and S-diols free base and/or acid addition salt in said solvent,
if
necessary by adding an acid, for example as a solid, a liquid, in a solution
or as a gas;
or mixtures thereof.
The acidic part of a RS-diol acid addition salt of the residue formed in step
i) is an
acid, which allows the selective dissolution of either R- or S-diol free base
and/or acid
addition salt and leaves the undissolved material enriched with the RS-diol
acid
addition salt.
The acid used for forming the RS-diol acid addition salt of the residue may
be:
CA 02511143 2005-06-20
WO 2004/056754 PCT/DK2003/000907
13
= present in the solvent before the initial non-racemic mixture of R- and S-
diol free base and/or acid addition salt is mixed with the solvent; and/or
= mixed with the solvent together with the initial non-racemic mixture of R-
and S-diol free base and/or acid addition salt; and/or
= mixed with the solvent after the initial non-racemic mixture of R- and S-
diol free base and/or acid addition salt is mixed with the solvent; and/or
= present in the initial non-racemic mixture of R- and S-diol free base and/or
acid addition salt during and/or prior to the mixing with the solvent.
Suitable acids for the formation of a residue/precipitate of RS-diol acid
addition salt
from an initial non-racemic mixture of R- and S-diol free base and/or acid
addition
salt are inorganic acids such as hydrochloric acid, hydrobromic acid and
sulphuric
acid or organic acids such as oxalic acid, p-toluenesulfonic acid,
methanesulfonic acid
and acetic acid. Hydrobromic acid, hydrochloric acid and oxalic acid are
preferred
acids. When these acids are used, a hydrobromide salt, hydrochloride salt or
oxalate
salt of the RS-diol is formed, preferably in crystalline form. Suitably, up to
10
equivalents of acid is used. Accordingly:
= 0.2-10 mol of acid may be used, such as 0.2-0.4 mol, or 0.4-0.6 mol, or 0.9-
1.1
mol or 1.8-2.2 mol of acid is used for each mol of S- and R-diol comprised in
the initial non-racemic mixture of R- and S-diol free base and/or acid
addition
salt; and/or
= 0.3-4.0 mol, such as 0.4-0.6 mol, or 0.9-1.1 mol or 1.8-2.2 mol of acid is
used
for each mol of RS-diol comprised in the residue/precipitate.
In order to increase the ionic strength of the solution, salts such as NaCl
may be added
to the solution before, during or after the RS-diol acid addition salt is
obtained in step
i). Those skilled in the art will know how to adjust the amount of salt added
to obtain
the desired effect.
Suitable solvents for the formation of a residue/precipitate of RS-diol acid
addition
salt from an initial non-racemic mixture of R- and S-diol free base and/or
acid
addition salt are polar and apolar solvents such as toluene, ethyl acetate,
diethylether,
CA 02511143 2005-06-20
WO 2004/056754 PCT/DK2003/000907
14
THF, alcohols such as iso-propylalcohol, acetonitrile, and ketones such as
acetone and
methyl isobutyl ketone, and water.
If the residue/precipitate formed in step i) is crystalline, the crystals are
separated
from the final solution phase, preferably by filtration or decanting. The
crystals are
optionally recrystallised by dissolving the crystals in a solvent, preferably
by heating,
and allowing the solution to cool, or by cooling to below ambient temperature.
Racemic citalopram may be formed from the crystalline racemic diol acid
addition
salt by ring closure. The racemic citalopram may be converted to a
pharmaceutically
acceptable salt thereof, preferably the HBr salt.
If the residue/precipitate formed in step i) is not crystalline, but amorphous
or an oil,
or mixtures thereof, steps i) and ii) may be repeated until a crystalline
product is
obtained. The crystals obtained are optionally recrystallised one or more
times as
described above. Racemic citalopram may be formed from the crystalline racemic
diol
acid addition salt by ring closure. The racemic citalopram may be converted
into a
pharmaceutically acceptable salt thereof, preferably the HBr salt.
An oily phase separated from the final solution phase is optionally subjected
to
conventional purification processes.
Thus, the RS-diol acid addition salt prepared according to the invention may
contain a
minor excess of the S-diol (or R-diol). It may thus be necessary to repeat
precipitation
(in particular crystallisation) of the RS-diol acid addition salt one or more
times in
order to obtain a racemic mixture. The final solution phase may be pooled
together
and the diol enantiomer contained herein may be isolated as described below.
If necessary, crystallisation of the RS-diol acid addition salt may be
initiated by
seeding with the racemic crystalline diol acid addition salt.
The RS-diol acid addition salt prepared according to the invention is
optionally
converted into other acid addition salts or the corresponding free base.
CA 02511143 2005-06-20
WO 2004/056754 PCT/DK2003/000907
According to a preferred embodiment of the invention, a free base of the RS-
diol or a
hydrochloride salt, hydrobromide salt or oxalate salt of the RS-diol is
obtained,
preferably in crystalline form in steps i), iia) and iib).
5
The final solution phase, extracts thereof, or a phase enriched with R- or S-
diol free
base and/or acid addition salt may be subjected to conventional purification
processes
(such as treatment with active carbon, chromatography etc.) before evaporation
of the
solvent, and/or it may be subjected to one or more further precipitations of
RS-diol
10 free base or RS-diol acid addition salt according to the invention, in
order to improve
the enantioineric purity of the diol enantiomer product.
The R- or S-diol free base and/or acid addition salt may be isolated from the
final
solution phase using conventional procedures such as evaporation of the
solvent, or in
15 case the final solution phase is acidic by basification followed by
separation of phases
or by extraction of R- or S-diol free base and/or acid addition salt followed
by
evaporation of the solvent.
The final solution phase, extracts thereof, or a phase enriched with R- or S-
diol free
base and/or acid addition salt may be subjected to conventional purification
processes
(such as treatment with active carbon, chromatography etc.) before the
isolation from
the R- or S-diol free base and/or acid addition salts. Suitably, R- or S-diol
may be
precipitated as a phosphate salt or an oxalate salt by methods known to those
skilled
in the art.
It has been found that the enantiomeric purity (the ratio between the wanted
isomer
and the sum of both isomers) of the S- or R-diol free base and/or acid
addition salt left
in the final solution phase may be as high as 97-98% or even higher (i.e.
better)
depending on the specific conditions used.
Accordingly, the S-diol (or R-diol) free base and/or acid addition salt
prepared
according to the invention may contain a minor amount of the R-diol (or S-
diol) free
base and/or acid addition salt. In one embodiment this minor amount may be
less than
CA 02511143 2005-06-20
WO 2004/056754 PCT/DK2003/000907
16
3%, or more preferred less than 2%, or most preferred less than 1% (the ratio
between
the isomer contained in a minor amount and the sum of both isomers).
The R-or S-diol free base and/or acid addition salt may be purified and
isolated from
said solvent or final solution phase as described above.
In one embodiment, R-diol free base or acid addition salt is obtained.
In another embodiment, S-diol free base or acid addition salt is obtained.
When R- or S-diol free base is obtained, it is optionally converted to acid
addition
salts thereof. When R- or S-diol acid addition salt is obtained, it is
optionally
converted to other acid addition salts or to the corresponding free base.
Enantiomerically-pure R- or S-diol free base and/or acid addition salt may be
mixed
with a non-racemic mixture of R- and S-diol free base and/or acid addition
salt to
obtain racemic diol free base and/or acid addition salt. Racemic diol free
base and/or
acid addition salt may then be obtained by one or more precipitations of
racemic diol
free base and/or an acid addition salt thereof, followed by recrystallisation
as
described above.
R- or S-citalopram free base and/or acid addition salt may be formed from the
corresponding R- or S-diol free base and/or acid addition salt by ring closure
with
retention of configuration. S-citalopram (or R-citalopram) free base and/or
acid
addition salt may optionally be converted to an acid addition salt thereof,
preferably
the oxalate salt and optionally recrystallised.
Ring closure of the R- or S-diol free base and/or acid addition salt may be
performed
via a labile ester intermediate, e.g. in the presence of tosyl-chloride, in a
basic
environment, as described in EP-B1-347 066. Then, the ring closing reaction
proceeds
with retention of the stereochemistry. R- or S-citalopram free base and/or
acid
CA 02511143 2005-06-20
WO 2004/056754 PCT/DK2003/000907
17
addition salt of an enantiomeric purity substantially equal to the starting
diol is then
obtained.
Ring closure of the obtained racemic diol free base and/or acid addition salt
may be
performed in an acidic environment, as described in US 4,650,884, or via a
labile
ester as described above. Thereby, racemic citalopram is obtained.
The thus-obtained enantiomerically-pure R- or S-citalopram free base and/or
acid
addition salt may be mixed with a non-racemic mixture of R- and S-citalopram
free
base and/or acid addition salt to obtain racemic citalopram free base and/or
acid
addition salt. Racemic citalopram free base and/or acid addition salt may then
be
obtained by one or more precipitations of citalopram free base or an acid
addition salt
thereof, followed by recrystallisation as described above.
One particular embodiment of the invention relates to a process for the
preparation of
racemic diol free base or an acid addition salt thereof and/or R- or S-diol as
the free
base or an acid addition salt thereof by the separation of an initial non-
racemic
mixture of R- and S-diol with more than 50% of one of the enantiomers into a
fraction
being enriched with S-diol or R-diol and a fraction consisting of RS-diol
wherein the
ratio of R-diol:S-diol is equal to 1:1 or closer to 1:1 than in the initial
mixture of R-
and S-diol wherein
i) RS-diol is precipitated from a solvent as the free base or as an acid
addition salt thereof;
ii) the precipitate formed is separated from the mother liquor;
iia) if the precipitate is crystalline it is optionally recrystallised one
or more times to form racemic diol;
iib) if the precipitate is not crystalline, steps i) and ii) are optionally
repeated until a crystalline precipitate is obtained and the
CA 02511143 2005-06-20
WO 2004/056754 PCT/DK2003/000907
18
crystalline precipitate is optionally recrystallised one or more
times to form racemic diol;
iii) the mother liquor is optionally subjected to further purification and S-
diol or R-diol is isolated from the mother liquor;
iv) the free bases of the diols obtained are optionally converted to acid
addition salts thereof or acid addition salts of the diols obtained are
optionally converted to other acid addition salts or acid addition salts
of the diols obtained are optionally converted to the corresponding free
bases.
Another particular embodiment of the invention relates to a process for the
preparation of raceinic diol free base or an acid addition salt thereof and/or
R- or S-
diol as the free base or an acid addition salt thereof by the separation of an
initial non-
racemic mixture of R- and S-diol with more than 50% of one of the enantiomers
into a
fraction being enriched with S-diol or R-diol and a fraction consisting of RS-
diol
wherein the ratio of R-diol:S-diol is equal to 1:1 or closer to 1:1 than in
the initial
mixture of R- and S-diol wherein
i) RS-diol is precipitated from a solvent as the free base or as an acid
addition salt thereof; or
R- or S-diol is dissolved into a solvent from the initial non-racemic
mixture of R- or S-diols as the free base or as an acid addition salt
thereof in said solvent, leaving a residue;
ii) the precipitate formed is separated from the mother liquor;
iia) if the precipitate is crystalline it is optionally recrystallised one
or more times to form racemic diol;
CA 02511143 2005-06-20
WO 2004/056754 PCT/DK2003/000907
19
sib) if the precipitate is not crystalline, steps i) and ii) are optionally
repeated until a crystalline precipitate is obtained and the
crystalline precipitate is optionally recrystallised one or more
times to form racemic diol;
iii) the mother liquor is optionally subjected to further purification and S-
diol or R-diol is isolated from the mother liquor;
iv) the free bases of the diols obtained are optionally converted to acid
addition salts thereof or acid addition salts of the diols obtained are
optionally converted to other acid addition salts or acid addition salts
of the diols obtained are optionally converted to the corresponding free
bases.
The invention is illustrated by the following examples, which may not be
construed as
limiting.
Examples
In the following examples optical purities were measured by Chiral SCFC (super
critical fluid chromatography) HPLC.
Example 1
Purification of S-diol by precipitation of racemic diol as the hydrochloride
salt
General method:
A mixture of R- and S-diols (as defined in the table below) (10 g) was
dissolved in
toluene (60 mL). Aqueous hydrochloric acid solution (32 mL, 1 M) was added,
and in
some cases solid sodium chloride was added (enough so that the concentration
of
NaCl in the water was approximately 1 M). The mixture was stirred overnight,
and
filtered. The residue was dried to give crystals of racemic diol
hydrochloride,
contaminated by some S-diol hydrochloride. The mother liquor was basified with
CA 02511143 2005-06-20
WO 2004/056754 PCT/DK2003/000907
aqueous ammonia solution to pH > 9, and the toluene layer was separated. The
aqueous layer was washed once more with toluene, and the combined toluene
extracts
were dried over magnesium sulfate and evaporated under reduced pressure to
give
mainly S-diol, contaminated with a small amount of R-diol. See table for
details.
5 Recovery of material was virtually quantitative, with the expected
partitioning of
weight between the respective samples.
Before Precipitation After Precipitation
Mixture' of Isomers Precipitate (mixture of R and Oil after basification,
S-diols) separation and evaporation
(enriched S-enantiomer)
S% R% S% R% S% R%
98.4 1.6 54 46 97.9 2.1*
95.4 4.6 55 45 98.7 1.3*
90.3 9.7 51 49 96.7 3.3
80 20 51 49 96.7 3.3
69 31 50 50 94.8 5.2
59 41 54 46 92 8.0
*Denotes that solid NaCl was added to the mixture, sufficient so that the
resulting
water phase was approximately 1 M in NaCl.
In the following examples optical purity is measured by Chiral HPLC.
Example 2
Purification of S-diol by precipitation of racemic diol free base
A solution of S-diol in acetonitrile (500 mL, ca. 50 - 55% w/w, S:R ratio
95.72:4.28)
at room temperature was cooled with stirring to -14 C. The mixture was seeded
with
almost-racemic diol (S:R ratio ca. 60:40) after every drop in temperature of 2
C.
After 16 hours the mixture was filtered, and the filter cake was dried.
Analysis of the
CA 02511143 2005-06-20
WO 2004/056754 PCT/DK2003/000907
21
filter cake indicated that the S:R ratio was 57.97:42.03. Analysis of the
mother liquor
indicated that the S:R ratio was 98.065:1.935.
Example 3
Purification of S-diol by precipitation of racemic diol free base
A solution of S-diol in acetonitrile (500 mL, ca. 50 - 55% w/w, S:R ratio
95.72:4.28)
at room temperature was cooled with stirring to -10 C with cooling at a rate
of 1
C/h. The mixture was seeded with almost-racemic diol (S:R ratio ca. 60:40)
after
every drop in temperature of 5 C. After 40 hours at -10 C the mixture was
filtered,
and the filter cake was dried. Analysis of the filter cake indicated that the
S:R ratio
was 59.19:40.81. Analysis of the mother liquor indicated that the S:R ratio
was
98.52:1.48.
Example 4
Purification of S-diol by precipitation of racemic diol as the hydrochloride
salt
General method:
A mixture of R- and S-diols (as defined in the table below) (1 g) was
dissolved in
toluene (10 mL). Aqueous hydrochloric acid solution (1.0 equivalent;
concentration as
defined in the table below) was added, and solid sodium chloride was added
(enough
so that the concentration of NaCl in the water was approximately 1 or 2 M; see
table
below). The mixture was stirred overnight, and filtered. The residue was dried
to give
crystals of racemic diol hydrochloride, contaminated by some S-diol
hydrochloride.
The mother liquor was basified with aqueous ammonia solution to pH > 9, and
the
toluene layer was separated. The aqueous layer was washed once more with
toluene,
and the combined toluene extracts were dried over magnesium sulfate and
evaporated
under reduced pressure to give mainly S-diol, contaminated with a small amount
of R-
diol. See table for details. Recovery of material was virtually quantitative,
with the
expected partitioning of weight between the respective samples.
CA 02511143 2005-06-20
WO 2004/056754 PCT/DK2003/000907
22
Before Precipitation After Precipitation
Mixture of Isomers Aqueous Aqueous Precipitate (mixture Oil after
HCl NaCl of R and S-diols) basification,
Conc. (M) Conc. (M) separation and
evaporation
(enriched S-
enantiomer)
S% R% S% R% S% R%
82.3 17.7 1.0 1.0 58.4 41.6 99.4 0.6
82.3 17.7 2.0 1.0 49.7 50.3 97.7 2.3
82.3 17.7 1.0 2.0 81.3 18.7 86.2 13.8
82.3 17.7 2.0 2.0 60.1 39.9 99.7 0.3
Example 5
Purification of S-diol by precipitation of racemic diol as p-toluenesulfonyl,
methanesulfonyl or acetate salts
General method:
A mixture of R- and S-diols (as defined in the table below) (1 g) was
dissolved in
toluene or ether (10 mL; as described in the table below). Aqueous NaCl
solution (1
M, 3 mL) was added. The acid (as defined in the table below) was added neat as
a
liquid. The mixture was stirred overnight, and filtered or decanted. The
residue was
dried to give an oil or a solid. The mother liquor was basified with aqueous
ammonia
solution to pH > 9, and the toluene or ether layer was separated. The aqueous
layer
was washed once more with toluene or ether, and the combined organic extracts
were
dried over magnesium sulfate and evaporated under reduced pressure to give
mainly a
solid or an oil. See table for details. Recovery of material was virtually
quantitative,
with the expected partitioning of weight between the respective samples.
CA 02511143 2005-06-20
WO 2004/056754 PCT/DK2003/000907
23
Before Precipitation After Precipitation
Mixture of Isomers Solvent Acid Precipitate (mixture Oil after
(equiv.) of R and S-diols) basification,
separation and
evaporation
(enriched S-
enantiomer)
S% R% S% R% S% R%
82.3 17.7 Toluene MsOH (1) 64.4 35.6 94.3 5.7
82.3 17.7 Toluene MsOH (2) 48.2 51.8 90.0 10.0
82.3 17.7 Ether MsOH (1) 62.9 37.1 91.0 9.0
82.3 17.7 Ether MsOH (2) 55.1 44.9 89.3 10.7
82.3 17.7 Toluene AcOH (1) 71.3 28.7 96.2 3.8
82.3 17.7 Toluene AcOH (2) 65.9 34.1 94.8 5.2
82.3 17.7 Ether AcOH (1) 65.0 35.0 91.6 8.4
82.3 17.7 Ether AcOH (2) 65.7 34.3 87.2 12.8
Example 6
Purification of S-diol by precipitation of a racemic diol salt in the absence
of
water
General method:
A mixture of R- and S-diols (as defined in the table below) (1 g) was
dissolved in
toluene or ether (10 mL; as described in the table below). The acid (as
defined in the
table below) was added neat as a solid. The mixture was stirred overnight, and
filtered. The residue was dried to give an oil or a solid. Water was added to
the mother
liquor, and the mother liquor was basified with aqueous ammonia solution to pH
> 9,
and the toluene or ether layer was separated. The aqueous layer was washed
once
more with toluene or ether, and the combined organic extracts were dried over
magnesium sulfate and evaporated under reduced pressure to give mainly a solid
or an
CA 02511143 2005-06-20
WO 2004/056754 PCT/DK2003/000907
24
oil. See table for details. Recovery of material was virtually quantitative,
with the
expected partitioning of weight between the respective samples.
Before Precipitation After Precipitation
Mixture of Isomers Solvent Acid Precipitate (mixture Oil after
(equiv.) of R and S-diols) basification,
separation and
evaporation
(enriched S-
enantiomer)
S% R% S% R% S% R%
82.3 17.7 Toluene TsOH (0.4) 54.9 45.1 90.9 8.1
82.3 17.7 Ether TsOH (0.4) 57.4 42.6 98.1 7.9
82.3 17.7 Toluene (CO2H)2 78.4 21.6 93 7
(0.2)
82.3 17.7 Toluene (CO2H)2 72.1 27.8 99.97 0.03
(0.4)
82.3 17.7 Toluene (CO2H)2 82.2 17.8 99.6 0.4
(1)
82.3 17.7 Ether (CO2H)2 58.0 42.0 97.7 2.3
(0.2)
82.3 17.7 Ether (CO2H)2 55.4 44.6 98.4 1.6
(0.4)
82.3 17.7 Ether (CO2H)2 72.0 28.0 99.5 0.5
(1)
Example 7
Purification of S-diol by precipitation of a racemic diol salt in the absence
of
water using various solvents
CA 02511143 2005-06-20
WO 2004/056754 PCT/DK2003/000907
General method:
A mixture of R- and S-diols (as defined in the table below) (1 g) was
dissolved in a
solvent (10 mL; as described in the table below). The acid (as defined in the
table
below) was added neat as a solid. The mixture was stirred overnight, and
filtered or
5 decanted if a precipitate had formed. Where a precipitate had formed, the
residue was
dried to give an oil or a solid. The mother liquor was evaporated, and the
residue was
taken up in a mixture of ether and water. This mixture was basified with
aqueous
ammonia solution to pH > 9, and the ether layer was separated. The aqueous
layer
was washed once more with ether, and the combined ether extracts were dried
over
10 magnesium sulfate and evaporated under reduced pressure to give mainly a
solid or an
oil. See table for details. Recovery of material was virtually quantitative,
with the
expected partitioning of weight between the respective samples.
CA 02511143 2005-06-20
WO 2004/056754 PCT/DK2003/000907
26
Before Precipitation After Precipitation
Mixture of Solvent Acid Precipitate (mixture Oil after
Isomers (equiv.) of R and S-diols) basification,
separation and
evaporation
(enriched S-
enantiomer)
S% R% S% R% S% R%
82.3 17.7 MeOH TsOH (0.4) No Precipitation
82.3 17.7 MeOH (C02H)2 No Precipitation
(0.2)
82.3 17.7 IPA TsOH (0.4) 51.5 48.5 91.6 8.4
82.3 17.7 IPA (CO2H)2 54.9 45.1 98.3 1.7
(0.2)
82.3 17.7 Acetonitrile TsOH (0.4) No Precipitation
82.3 17.7 Acetonitrile (CO2H)2 57.2 42.8 97.2 2.8
(0.2)
82.3 17.7 THE TsOH (0.4) No Precipitation
82.3 17.7 THE (C02H)2 53.2 46.8 98.9 1.1
(0.2)
82.3 17.7 Acetone TsOH (0.4) No Precipitation
82.3 17.7 Acetone (C02H)2 56.7 43.3 98.2 1.8
(0.2)
82.3 17.7 MIBK TsOH (0.4) 56.8 43.2 98.5 1.5
82.3 17.7 MIBK (C02H)2 58.7 41.3 99.6 0.4
(0.2)
Example 8
Purification of S-diol by precipitation of racemic diol oxalate
CA 02511143 2005-06-20
WO 2004/056754 PCT/DK2003/000907
27
General method:
A mixture of R- and S-diols (as defined in the table below) (1 g) was
dissolved in
toluene (10 inL). An aqueous solution of NaCl was added (1 M, 3 mL) and oxalic
acid
(as defined in the table below) was added neat as a solid. The mixture was
stirred
overnight, and filtered or decanted if a precipitate had formed. Where a
precipitate
had formed, the residue was dried to give an oil or a solid. The mother liquor
was
basified with aqueous ammonia solution to pH > 9, and the toluene layer was
separated. The aqueous layer was washed once more with toluene, and the
combined
toluene extracts were dried over magnesium sulfate and evaporated under
reduced
pressure to give mainly a solid or an oil. See table for details. Recovery of
material
was virtually quantitative, with the expected partitioning of weight between
the
respective samples.
Before Precipitation After Precipitation
Mixture of Oxalic Acid Precipitate (mixture Oil after basification, separation
Isomers (equiv.) of R and S-diols) and evaporation (enriched S
enantiomer)
S% R% S% R% S% R%
82.3 17.7 0.2 51.8 48.2 98.5 1.5
82.3 17.7 0.4 62.6 37.4 99.8 0.2
82.3 17.7 1.0 58.6 41.4 97.0 3.0
82.3 17.7 2.0 56.7 43.3 92.7 7.3
Example 9
Purification of S-diol by precipitation of racemic diol hydrochloride in water
General method:
A mixture of R- and S-diols (as defined in the table below) (1 g) was stirred
with an
aqueous solution of HCl (1 equivalent; see table for concentration). The
mixture was
stirred overnight, and sufficient NaCl was added (as a solid) so that the
concentration
of NaCl was 1 M. The mixture was filtered to give a solid. To the mother
liquor was
CA 02511143 2005-06-20
WO 2004/056754 PCT/DK2003/000907
28
added water and ether, was basified with aqueous ammonia solution to pH > 9,
and
the ether layer was separated. The aqueous layer was washed once more with
ether,
and the combined ether extracts were dried over magnesium sulfate and
evaporated
under reduced pressure to give mainly a solid or an oil. See table for
details. Recovery
of material was virtually quantitative, with the expected partitioning of
weight
between the respective samples.
Before Precipitation After Precipitation
Mixture of HC1 conc. Precipitate (mixture Oil after basification, separation
Isomers (M) of R and S-diols) and evaporation (enriched S-
enantiomer)
S% R% S% R% S% R%
82.3 17.7 1 59.4 40.6 99.2 0.8
82.3 17.7 2 63.7 36.3 99.3 0.7
Example 10
Purification of S-diol by preferential dissolution of S-diol hydrochloride in
water
General method:
A mixture of R- and S-diol hydrochloride salts (17.7 : 82.3; 5.5 g) was
stirred with an
aqueous solution of NaCl (1 M, 12 mL). The mixture was stirred overnight, and
was
filtered to give a solid. To the mother liquor was added water and ether, was
basified
with aqueous ammonia solution to pH > 9, and the ether layer was separated.
The
aqueous layer was washed once more with ether, and the combined ether extracts
were dried over magnesium sulfate and evaporated under reduced pressure to
give
mainly a solid or an oil. The residue from filtration contained R-diol and S-
diol in a
ratio of 1.0 : 99Ø The product from work-up of the filtrate contained R-diol
and S-
diol in a ratio of 38.8 : 61.2. Recovery of material was virtually
quantitative, with the
expected partitioning of weight between the respective samples.
